Christopher Puckett, DO
Family Medicine · Owens Cross Roads, ALNPI 1679060388
Payments from drug & device makers
Across 369 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$675
- Bayer$455
- Amgen$428
- GSK$397
- Pfizer$368
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,725100%
- Entertainment$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 135 | $1,552 |
| Lilly USA, LLC | 40 | $675 |
| Bayer | 23 | $455 |
| Amgen | 23 | $428 |
| GSK | 21 | $397 |
| Pfizer | 20 | $368 |
| Merck | 13 | $224 |
| Boehringer Ingelheim | 11 | $209 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $206 |
| Dynavax Technologies Corporation | 9 | $189 |
| AbbVie | 8 | $136 |
| AstraZeneca | 7 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $99 |
| Exact Sciences | 6 | $97 |
| Astellas Pharma US Inc | 5 | $78 |
| Abbott | 4 | $69 |
| Kowa Pharmaceuticals America, Inc. | 5 | $68 |
| Sumitomo Pharma America, Inc. | 3 | $63 |
| Sanofi Pasteur Inc. | 2 | $59 |
| Phathom Pharmaceuticals, Inc. | 5 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $51 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Dexcom, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Novartis | 1 | $20 |
| Optos, Inc. | 1 | $14 |
How this compares
$5,739 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 105 | $115,160 |
| OzempicSemaglutide | 96 | $93,475 |
| JardianceEmpagliflozin | 88 | $88,023 |
| EliquisApixaban | 37 | $39,843 |
| RybelsusSemaglutide | 22 | $34,471 |
| MyrbetriqMirabegron | 28 | $22,175 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $20,718 |
| XareltoRivaroxaban | 18 | $18,784 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $16,994 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $16,234 |
| TrulicityDulaglutide | 11 | $15,657 |
| Repatha SureclickEvolocumab | 14 | $7,450 |
| Repatha SyringeEvolocumab | 14 | $7,426 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,533 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 133 | $3,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $675 | $130,818116 claims |
| Novo NordiskOzempic, Rybelsus | $1,552 | $127,946118 claims |
| Boehringer IngelheimJardiance | $209 | $88,02388 claims |
| PfizerEliquis | $368 | $39,84337 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $126 | $24,25148 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $22,17528 claims |
| GSKTrelegy Ellipta | $397 | $16,23417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Owens Cross Roads
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.